Evidence for a role of phosphodiesterase 4 in lipopolysaccharide-stimulated prostaglandin E2 production and matrix metalloproteinase-9 activity in human amniochorionic membranes

被引:48
作者
Oger, S [1 ]
Méhats, C [1 ]
Dallot, E [1 ]
Cabrol, D [1 ]
Leroy, MJ [1 ]
机构
[1] Univ Paris 05, Fac Sci Pharmaceut & Biol, INSERM, Unite 427, F-75270 Paris, France
关键词
D O I
10.4049/jimmunol.174.12.8082
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Chorioamniotic infection is a leading cause of preterm premature rupture of fetal membranes (amnion and chorion). Bacterial infection induces an inflammatory response characterized by elevated production of proinflammatory cytokines; the latter activate the production of both PGs that stimulate uterine contractions, and matrix metalloproteinases (MMPs) that degrade the extracellular matrix of the chorioamniotic membranes. The inflammatory response is under the control of cAMP content, which is partly regulated by phosphodiesterases (PDE). In this study, we investigated the role of the PDE4 family in the inflammatory process triggered by LPS in a model of amniochorionic explants. We found that PDE4 family is the major cAMP-PDE expressed in human fetal membranes and that PDE4 activity is increased by LPS treatment. Selective inhibition of PDE4 activity affected LPS signaling, because PDE4 inhibitors (rolipram and/or cilomilast) reduced the release of the proinflammatory cytokine TNF-alpha and increased the release of the anti-inflammatory cytokine IL-10. PDE4 inhibition reduced cyclooxygenase-2 protein expression and PGE2 production and also modulated MMP-9, a key mediator of the membrane rupture process, by inhibiting pro-MMP-9 mRNA expression and pro-MMP-9 activity. These results demonstrate that the PDE4 family participates in the regulation of the inflammatory response associated with fetal membrane rupture during infection. The PDE4 family may be an appropriate pharmacological target for the management of infection-induced preterm delivery.
引用
收藏
页码:8082 / 8089
页数:8
相关论文
共 49 条
[41]   Suppression of granulocyte/macrophage colony-stimulating factor release from human monocytes by cyclic AMP-elevating drugs: role of interleukin-10 [J].
Seldon, PM ;
Giembycz, MA .
BRITISH JOURNAL OF PHARMACOLOGY, 2001, 134 (01) :58-67
[42]   Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors [J].
Souness, JE ;
Aldous, D ;
Sargent, C .
IMMUNOPHARMACOLOGY, 2000, 47 (2-3) :127-162
[43]   Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease [J].
Spina, D .
DRUGS, 2003, 63 (23) :2575-2594
[44]   The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-α ex vivo [J].
Timmer, W ;
Leclerc, V ;
Birraux, G ;
Neuhäuser, M ;
Hatzelmann, A ;
Bethke, T ;
Wurst, W .
JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (03) :297-303
[45]   Expression of interleukin-10 in human gestational tissues [J].
Trautman, MS ;
Collmer, D ;
Edwin, SS ;
White, W ;
Mitchell, MD ;
Dudley, DJ .
JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION, 1997, 4 (05) :247-253
[46]   ALTERATIONS IN CELLULAR ADHESION AND APOPTOSIS IN EPITHELIAL-CELLS OVEREXPRESSING PROSTAGLANDIN-ENDOPEROXIDE-SYNTHASE-2 [J].
TSUJII, M ;
DUBOIS, RN .
CELL, 1995, 83 (03) :493-501
[47]  
VERGHESE MW, 1995, J PHARMACOL EXP THER, V272, P1313
[48]   MODULATION OF AMNIOTIC ADENYLATE-CYCLASE AND CAMP-PHOSPHODIESTERASE BY PROSTAGLANDINS E(1) AND F2-ALPHA [J].
VESCE, F ;
TARABBIA, C ;
FARINA, A ;
TRAVAGLI, S ;
PARESCHI, MC ;
PORTOLAN, A ;
BIONDI, C .
GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 1994, 37 (02) :77-82
[49]   Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E(2), and matrix metalloproteinases [J].
Zhang, YH ;
DeWitt, DL ;
McNeely, TB ;
Wahl, SM ;
Wahl, LM .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (05) :894-900